| pubmed-article:3383462 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:3383462 | lifeskim:mentions | umls-concept:C0031327 | lld:lifeskim |
| pubmed-article:3383462 | lifeskim:mentions | umls-concept:C0016610 | lld:lifeskim |
| pubmed-article:3383462 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:3383462 | lifeskim:mentions | umls-concept:C0031140 | lld:lifeskim |
| pubmed-article:3383462 | lifeskim:mentions | umls-concept:C0442120 | lld:lifeskim |
| pubmed-article:3383462 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:3383462 | pubmed:dateCreated | 1988-7-29 | lld:pubmed |
| pubmed-article:3383462 | pubmed:abstractText | Kinetics of fosfomycin were investigated in six patients undergoing continuous ambulatory peritoneal dialysis. Each subject received both an i.v. and an i.p. 1 g dose of fosfomycin with a one week washout between doses. Fosfomycin was assayed by a microbiological diffusion technique. After intravenous injection the fosfomycin serum kinetic parameters were as followed: elimination half-life (t1/2 beta) 38.4 +/- 8.7 h; volume of distribution 0.32 +/- 0.02 l/kg; total plasma clearance 7.0 +/- 1.4 ml/min and peritoneal clearance 3.2 +/- 0.2 ml/min. Dialyzate fosfomycin concentrations reached a maximum mean value of 32.2 +/- 2.8 micrograms/ml at 4 h post-injection and fosfomycin was detectable in dialyzate samples for up to 72 hours post-dosing. After intraperitoneal instillation, fosfomycin appeared in the serum rapidly and the mean peak plasma concentration was 36.2 +/- 2.8 micrograms/ml at the 4th h. The absorption rate (ka) was 0.580 +/- 0.039 h-1 and the absorption of fosfomycin from peritoneal space was 68.4 +/- 6.0%. These data suggest a bidirectional exchange through the peritoneal membrane. Intraperitoneal administration of 1 g either 48 h apart for anephric patients or 36 h apart for patients with residual renal function may achieve therapeutic serum concentrations. | lld:pubmed |
| pubmed-article:3383462 | pubmed:language | eng | lld:pubmed |
| pubmed-article:3383462 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3383462 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:3383462 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:3383462 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:3383462 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:3383462 | pubmed:issn | 0301-0430 | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:BouchetJ LJL | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:QuentinCC | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:AparicioMM | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:PotauxLL | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:AlbinHH | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:de... | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:VinçonGG | lld:pubmed |
| pubmed-article:3383462 | pubmed:author | pubmed-author:Martin-Dupont... | lld:pubmed |
| pubmed-article:3383462 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:3383462 | pubmed:volume | 29 | lld:pubmed |
| pubmed-article:3383462 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:3383462 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:3383462 | pubmed:pagination | 35-40 | lld:pubmed |
| pubmed-article:3383462 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:meshHeading | pubmed-meshheading:3383462-... | lld:pubmed |
| pubmed-article:3383462 | pubmed:year | 1988 | lld:pubmed |
| pubmed-article:3383462 | pubmed:articleTitle | Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis. | lld:pubmed |
| pubmed-article:3383462 | pubmed:affiliation | Department of Clinical Nephrology, Pellegrin-Tripode Hospital, Bordeaux, France. | lld:pubmed |
| pubmed-article:3383462 | pubmed:publicationType | Journal Article | lld:pubmed |
